WallStreetZenWallStreetZen

NASDAQ: GRCE
Grace Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GRCE stock forecasts and price targets.

Forecast return on equity

Is GRCE forecast to generate an efficient return?

Company
15.58%
Industry
21.29%
Market
171.95%
GRCE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GRCE forecast to generate an efficient return on assets?

Company
15%
Industry
21.83%
GRCE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GRCE earnings per share forecast

What is GRCE's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
-$0.47
Avg 3 year Forecast
$0.36

GRCE revenue forecast

What is GRCE's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$5.1M
Avg 2 year Forecast
$23.0M
Avg 3 year Forecast
$102.0M

GRCE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GRCE$1.94N/AN/A
INMB$1.45N/AN/A
ATHE$2.16$12.00+455.56%Strong Buy
TVGN$5.90N/AN/A
EXOZ$4.13N/AN/A
View Top Biotech Stocks

Grace Therapeutics Stock Forecast FAQ

What is GRCE's earnings growth forecast for 2027-2029?

(NASDAQ: GRCE) Grace Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.

Grace Therapeutics's earnings in 2026 is -$20,221,000.On average, 4 Wall Street analysts forecast GRCE's earnings for 2027 to be -$14,483,238, with the lowest GRCE earnings forecast at -$16,492,169, and the highest GRCE earnings forecast at -$12,148,250. On average, 4 Wall Street analysts forecast GRCE's earnings for 2028 to be -$9,977,342, with the lowest GRCE earnings forecast at -$10,307,606, and the highest GRCE earnings forecast at -$9,497,722.

In 2029, GRCE is forecast to generate $7,509,827 in earnings, with the lowest earnings forecast at $7,215,324 and the highest earnings forecast at $7,730,704.

If you're new to stock investing, here's how to buy Grace Therapeutics stock.

What is GRCE's revenue growth forecast for 2027-2029?

(NASDAQ: GRCE) Grace Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.61%.

Grace Therapeutics's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast GRCE's revenue for 2027 to be $107,283,243, with the lowest GRCE revenue forecast at $0, and the highest GRCE revenue forecast at $220,877,265. On average, 4 Wall Street analysts forecast GRCE's revenue for 2028 to be $482,774,594, with the lowest GRCE revenue forecast at $0, and the highest GRCE revenue forecast at $993,947,693.

In 2029, GRCE is forecast to generate $2,145,664,860 in revenue, with the lowest revenue forecast at $2,061,521,140 and the highest revenue forecast at $2,208,772,650.

What is GRCE's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: GRCE) forecast ROA is 15%, which is lower than the forecast US Biotechnology industry average of 21.83%.

What is GRCE's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: GRCE) Grace Therapeutics's current Earnings Per Share (EPS) is -$1.17. On average, analysts forecast that GRCE's EPS will be -$0.69 for 2027, with the lowest EPS forecast at -$0.78, and the highest EPS forecast at -$0.58. On average, analysts forecast that GRCE's EPS will be -$0.47 for 2028, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.45. In 2029, GRCE's EPS is forecast to hit $0.36 (min: $0.34, max: $0.37).

What is GRCE's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: GRCE) forecast ROE is 15.58%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.